We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00186355
First Posted: September 16, 2005
Last Update Posted: May 14, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Stanford University
  Purpose
To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.

Condition Intervention
Lymphoma, Non-Hodgkin Procedure: high dose chemo then auto hematopoietic cell transplant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Enrichment and Purging of Stem Cells in the Treatment of Non-Hodgkin's Lymphoma

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • PCR positivity in peripheral blood cell collections after cyclophosphamide

Secondary Outcome Measures:
  • Enrichment of hematopoietic stem cells

Enrollment: 97
Study Start Date: October 2003
Study Completion Date: February 2010
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Detailed Description:
To study the use of peripheral blood stem cells which have been treated in an effort to remove tumor cells. The researchers hope to learn whether or not this will be more effective in removing the tumor cells as compared to other methods of purging (the removal of cancer cells).
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:- relapsed NHL

Exclusion Criteria:- liver dysfunction

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00186355


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
National Institutes of Health (NIH)
Investigators
Principal Investigator: Robert S Negrin Stanford University
  More Information

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00186355     History of Changes
Other Study ID Numbers: BMT4IJ
77063 ( Other Identifier: Stanford University Alternate IRB Approval Number )
12170 ( Other Identifier: Stanford IRB )
First Submitted: September 13, 2005
First Posted: September 16, 2005
Last Update Posted: May 14, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases